Table 1. Specific molecular alterations and approved drugs in Europe (at time of writing).

Gene	Molecular alteration	Approved drugs
EGFR	Activating mutations	Erlotinib, gefitinib, afatinib, osimertinib
	Resistance T790M mutation	Osimertinib
BRAF	V600 mutation	Dabrafenib + trametinib
ALK	Translocation	Crizotinib, alectinib, ceritinib, brigatinib
ROS1	Translocation	Crizotinib